Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Viloxazine(click to collapse)
1/4 selected
Viloxazine
QELBREE
Serotonin-Norepinephrine Modulating Agent
FDA-approved indications
- Attention-deficit/hyperactivity disorder (adults; pediatric 6+)
Off-label uses
- Anxiety disorders (with ADHD)
Half-life7 hours
Decision GuideWhen to pick each / when to consider an alternative
Viloxazine
Consider when
- Pediatric ADHD (ages 6–17) — FDA-approved ER formulation; newest non-stimulant option with novel NRI + 5-HT modulation
- ADHD with comorbid anxiety — serotonergic component may benefit comorbid anxiety; non-stimulant avoids anxiety worsening
- Stimulant refusal or contraindication — non-scheduled alternative; no abuse potential
- Rapid onset for a non-stimulant — clinical improvement seen within 1 week in trials; faster than atomoxetine's 4–6 weeks
- +1 more
Consider an alternative when
- Adult ADHD — FDA-approved only for children/adolescents 6–17; adult use is off-label with limited data
- Somnolence is problematic — 11–16% across doses; may impair daytime function
- Nausea sensitivity — GI side effects (nausea, vomiting, decreased appetite) are common dose-dependent AEs
- Long-term data needed — newest agent with limited long-term safety and efficacy data compared to atomoxetine or guanfacine
- +1 more
| Axis | Viloxazine SNRI-ADHD |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Mania / hypomania induction | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
| Metabolic | |
Appetite suppression / anorexia | |
| Cardiac | |
QTc prolongation | |
Blood pressure elevation | |
Heart rate / tachycardia | |
| GI | |
Nausea / GI (general) | |
| Sexual | |
Sexual dysfunction | |
| Interactions | |
CYP interactions / DDI profile | |
| Pregnancy | |
Lactation / breastfeeding safety | |